Search by Ticker
The following stock analysis is based on 7.8 years of data (i.e. since Oct 31, 2012). All the stock history has been downloaded.
Abiomed trades on the NasdaqGS exchange in USD dollars.
It is in the healthcare sector.
It is currently trading at $294.87 ($300.02 the previous day).
The next reporting date is in 78 days (2020 10 29).
CNN estimates profits for the upcoming quarter will be $0.99 per share ($202.9M). The current Canada / US exchange rate is 1.3303.
Over the past 12 months, $0 worth of shares have been purchased and $7377059 worth of shares have been sold by insiders.
The year over year average increase is 26.6% per year assuming steady exponential growth. The actual 5 year average is 43.5. Details on the individual increase in one year intervals is provided below.
|Past Performance||Average Price||Percent Change|
|1 year||191.44450215054||-41.2||- Below Average|
|2 year||325.55754864865||19.6||- Below Average|
|3 year||272.1759832636||115.7||+ Above Average|
|4 year||126.16792682927||32.4||- Below Average|
|5 year||95.314641509434||91||+ Above Average|
The worst drop it has had in recent years is -71.0%. It has a dropping shape to the stock curve, which means the stock has to be watched closely. If the financials are good, it could be very profitable, however if not it may not recover and should be sold.
Abiomed is a manufacturer of medical implant devices, including the AbioCor artificial heart and Impella. For example, they acquired Impella technology in 2005 and have since received a series of FDA approvals. Overall, Abiomed engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients.
It's main office is located in Danvers, Massachusetts. There are three additional offices located in Germany (Berlin and Aachen) and Japan. The CEO is Michael R. Minogue, who joined Abiomed in 2004.
They have invested more than $100 million over the past five years in clinical research on the Impella heart pump platform. They have one of the most complete and extensive post-market surveillance programs in the medical device industry, that includes the Impella Quality Assurance (IQ) Database, the FDA-audited cVAD Study, and real-time monitoring of patients on Impella support through industry-leading 24x7 clinical support services.
Additionally, Abiomed plans to continue to actively support clinical research, including two randomized controlled trials, in 2019 that include:
ABIOMED (ABMD) Earnings and Revenues Beat Estimates in Q1Thu, 06 Aug 2020 13:26:01 ABIOMEDand's (ABMD) flagship Impella saw decline in revenues internationally and within the United States, in Q1.... Read Full Article
Abiomed (ABMD) Tops Q1 Earnings and Revenue EstimatesThu, 06 Aug 2020 12:25:12 Abiomed (ABMD) delivered earnings and revenue surprises of 176.19% and 19.26%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?... Read Full Article
Abiomed Announces Q1 FY 2021 Revenue of $165 Million and 21% Operating MarginThu, 06 Aug 2020 11:00:00 Abiomed announces Q1 FY 2021 revenue of $165 million and 21% operating margin.... Read Full Article
ABIOMED (ABMD) to Report Q1 Earnings: Whatand's in the Offing?Tue, 04 Aug 2020 12:50:12 The commercial rollout of ABIOMEDand's (ABMD) Impella 5.5 is expected to have progressed steadily through the fiscal first quarter.... Read Full Article
Abiomed’s Impella Scores Emergency FDA Nod For Covid-19 PatientsTue, 04 Aug 2020 12:39:18 Abiomed (ABMD) has announced that the US Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for left-sided Impella heart pumps to provide left ventricular unloading and support to COVID-19 patients who are undergoing ECMO treatment and ...... Read Full Article
Abiomed heart pump gets second FDA emergency use nod for COVID-19 patientsTue, 04 Aug 2020 12:05:34 Medical device maker Abiomed Inc said on Tuesday the U.S. Food and Drug Administration granted its left-sided heart pumps emergency use authorization to help patients suffering from COVID-19-related heart and lung failures. COVID-19, the respiratory disease caused by ...... Read Full Article
Abiomedand's stock rises on second COVID-19-related EUA for heart pumpTue, 04 Aug 2020 11:48:00 Shares of Abiomed Inc. rallied 2.0% in premarket trading on Tuesday after the company said its Impella heart pump had received an emergency use authorization from the Food and Drug Administration as a treatment for some COVID-19 patients. The heart pump ...... Read Full Article
FDA Issues Emergency Use Authorization for Impella Heart Pumps to Provide Unloading Therapy to COVID-19 PatientsTue, 04 Aug 2020 11:00:00 The United States Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for left-sided Impella heart pumps to provide left ventricular unloading and support to COVID-19 patients who are undergoing ECMO treatment and develop pulmonary edema or ...... Read Full Article
How Much Is Abiomed, Inc. (NASDAQ:ABMD) Paying Its CEO?Fri, 31 Jul 2020 12:02:25 This article will reflect on the compensation paid to Mike Minogue who has served as CEO of Abiomed, Inc...... Read Full Article
Large Multi-Center Study in Japan Finds High Survival Rates with Use of Impella Heart PumpThu, 30 Jul 2020 12:00:00 A three-year, investigator-led, prospective study of Japanese patients who received an Impella heart pump finds use of Impella is associated with a 77% survival rate at 30 days in AMI cardiogenic shock patients. The historic survival rate for cardiogenic shock is approximately 50%. ...... Read Full Article
FMS vs. ABMD: Which Stock Should Value Investors Buy Now?Wed, 22 Jul 2020 15:40:03 FMS vs. ABMD: Which Stock Is the Better Value Option?... Read Full Article
Abiomed Gets FDA Nod for Data Streaming Via Impella ConnectMon, 20 Jul 2020 12:19:12 Abiomedand's (ABMD) announcement of the FDA approval of one-way digital data streaming from the Impella Connect interface can boost patient outcomes further.... Read Full Article
Abiomed First Quarter Fiscal 2021 Earnings and Conference Call NotificationThu, 16 Jul 2020 11:00:00 Abiomed announced that on Thursday, August 6, 2020, the Company will release financial results for the first quarter of fiscal 2021.... Read Full Article
FDA Approves Data Streaming from the Impella Console, Setting the Stage for Artificial Intelligence Algorithms to Further Improve Patient OutcomesThu, 16 Jul 2020 11:00:00 The United States Food and Drug Administration (FDA) has approved one-way digital data streaming during patient support from Abiomedand's (NASDAQ: ABMD) Automated Impella Controller (AIC), the external console used with Impella heart pumps. The data streaming capability is facilitated through ...... Read Full Article
Did Hedge Funds Make The Right Call On ABIOMED, Inc. (ABMD) ?Sun, 12 Jul 2020 23:38:17 The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge ...... Read Full Article
Are These Medical Stocks Cruising Toward Big Gains? Hereand's A Bullish SignThu, 09 Jul 2020 14:00:26 Medical stocks could be making a comeback this year. The best-performing among them include medical technology companies with high Composite Ratings, a key metric measuring growth.... Read Full Article
MiMedx Announces Concurrent $150 Million Private Equity and Debt FinancingsThu, 02 Jul 2020 13:00:10 MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced the closing of concurrent $150 million private equity and debt financings, consisting of an equity financing ...... Read Full Article
Study Finds 84% Survival Rate in Patients in Cardiogenic Shock and Other Challenging Cardiac Conditions with the New Impella 5.5 with SmartAssistWed, 01 Jul 2020 11:00:00 The first published United States experience of patients who received Abiomed’s newest heart pump, Impella 5.5 with SmartAssist, finds 84% of the patients survived to explant with 76% native heart recovery. The study was published in the July edition of the American ...... Read Full Article
Edited Transcript of ABMD earnings conference call or presentation 30-Apr-20 12:00pm GMTWed, 17 Jun 2020 14:29:48 Q4 2020 ABIOMED Inc Earnings Call... Read Full Article
ABIOMED Unveils Digital Platform CAMP PCI for CAD TreatmentWed, 17 Jun 2020 10:28:10 ABIOMEDand's (ABMD) new digital platform helps to deliver better patient outcomes for those suffering from CAD.... Read Full Article